Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Share and share not alike for CGT

Article Abstract:

UK capital gains tax (CGT) is levied on gains made by selling shares. Calculating the amount due is complicated by indexing over the time the shares have been held. There are different rules for different types of share in the UK. Preference shares and ordinary shares are treated in the same way, as are shares in investment trusts and unit trusts. Gains on warrants are calculated from when warrants are sold or when shares are sold that have been acquired by using the warrant.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
United Kingdom, Taxation, Securities, Capital gains tax, Securities taxes

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Share and share alike keeps wealth flowing: North West Water is to share its surplus profitswith customers and shareholders. Investors should be pleased that the water industry is keen toavoid the trap electricity companies fell into

Article Abstract:

North West Water is to share its 180 million pounds sterling surplusprofits with customers and shareholders, following the lead set by Severn Trent in November.The water companies have attracted criticism since their privatisation in 1989, from customerswho believe they are paying over the odds, when infrastructure costs have been lower thanexpected. Ofwat stated that any efficiency savings should be shared equally by shareholders andcustomers.

Author: Ahmad,Sameena
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Water Supply and Irrigation Systems, Water Utilities, Investor relations, North West Water Group PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Getting better endowed: every week, thousands of investors receive 10,000 pounds sterling or more as their endowment policies mature. Insurers are keen for the proceeds to be reinvested with them. But many investors would be better off going elsewhere

Article Abstract:

Insurers are keen for investors to reinvest the proceeds of endowment policies, and are offering discounts such as improved allocation rates. However investors may be tempted by poor value, or unsuitable products and may not be aware that they could invest their lump sums elsewhere. It is best not to place the funds straight back into another endowment as unit and investment trust Peps can produce better returns.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Insurance NEC, Other Direct Insurance (except Life, Health, and Medical) Carriers, Purchasing, Insurance, Endowment insurance

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Similar abstracts:
  • Abstracts: An investigation of auditor judgments of the effect of preliminary analytical procedures on the extent of substantive testing
  • Abstracts: Interfering effects of the task demands of grip force and mental processing on isometric shoulder strength and muscle activity
  • Abstracts: Hit singles: There are a number of different strategies that investors can employ to utilize their single company Pep allowance depending on their attitude to risk and their tax bracket
  • Abstracts: Pension transfers: The appliance of science. Beware the hype in Pep managers' final sales pitches: Pep managers have just a few more weeks to sell their products or they'll miss out on your cash for ever. Nor surprisingly, they're putting a big effort into advertising and marketing
  • Abstracts: Emergers are everywhere. The message from the yield curve: An early economic recovery seems unlikely-but investors may not need to worry about this
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.